VIEW-Iran

Completed

A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine

A Multi-centre, Prospective, Non-interventional Study Investigating the Effect of Victoza® in Patients With Type 2 Diabetes in Iran Followed in a Real World Setting

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

839

actual

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c ≤12%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03888157

Org study IDNN2211-4438

Secondary IDU1111-1213-4238World Health Organization (WHO)

Timeline

Milestones

Study start2019-03-10actual

Study first posted2019-03-25actual

Primary completion2020-10-21actual

Study completion2020-10-21actual

Last update posted2021-07-14actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Sampling methodNon probability sample

Study population text

Patients with T2DM in Iran judged by the study doctor for whom Victoza® is indicated are eligible to participate in the study.

Inclusion criteria

•Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)

•Male or female, age greater than or equal to 18 years at the time of signing informed consent

•The decision to initiate treatment with commercially available Victoza® has been made by the patient and the treating physician before and independently from the decision to include the patient in this study

•Patients diagnosed with type 2 diabetes mellitus (T2DM), with treatment planned according to the Iranian label for Victoza® at treatment initiation

•Available glycated haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of treatment with Victoza®

Exclusion criteria

•Previous participation in this study. Participation is defined as having given informed consent in this study

•Known or suspected hypersensitivity to Victoza® or related products

•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Endpoints (15)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Weight & body composition

Glycemic / diabetes

Patient-reported / QoL

Safety / tolerability / PK

Weight & body composition

3 endpoints

Secondary/protocol endpoint

Change in body weight (kilogram)

Time frame:Week 0, week 26

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in body weight (percentage)

Time frame:Week 0, week 26

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change in waist circumference

Time frame:Week 0, week 26

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

3 endpoints

Primary/protocol endpoint

Change in glycated haemoglobin A1c (HbA1c) (percentage)

Time frame:Week 0, week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Primary/protocol endpoint

Change in HbA1c (mmol/mol)

Time frame:Week 0, week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in fasting blood glucose (FBG) (self-measured)

Time frame:Week 0, week 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Cardiometabolic biomarkers

5 endpoints

Secondary/protocol endpoint

Change in total cholesterol (TC)

Time frame:Week 0, week 26

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in low density lipoprotein cholesterol (LDL-C)

Time frame:Week 0, week 26

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in high density lipoprotein cholesterol (HDL-C)

Time frame:Week 0, week 26

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in triglyceride (TG)

Time frame:Week 0, week 26

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in free fatty acid (FFA)

Time frame:Week 0, week 26

Free fatty acids, change

change from baseline, improvement

Patient-reported / QoL

2 endpoints

Secondary/protocol endpoint

Changes in quality of life (EQ-5D index score)

Time frame:Week 0, week 26

EQ-5D index

change from baseline, improvement

Secondary/protocol endpoint

Changes in quality of life (EQ VAS)

Time frame:Week 0, week 26

EQ-5D VAS

change from baseline, improvement

Safety / tolerability / PK

2 endpoints

Secondary/protocol endpoint

Number of patients permanently discontinuing treatment with Victoza®

Time frame:Week 26

Discontinuation due to AE

event count, event

Secondary/protocol endpoint

Reasons for permanent treatment discontinuations

Time frame:Week 26

Discontinuation due to AE

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.